Royal Bank of Canada
SAGE

Royal Bank of Canada’s Sage Therapeutics SAGE Stock Holding History

Royal Bank of Canada’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,879
Closed -$53K – 7476
2025
Q2 		$53K Buy
5,879
+2,108
+56% +$15.5K ﹤0.01% 5896
2025
Q1 		$30K Sell
3,771
-3,474
-48% -$25.4K ﹤0.01% 5779
2024
Q4 		$39K Sell
7,245
-11,803
-62% -$72.2K ﹤0.01% 5815
2024
Q3 		$138K Sell
19,048
-3,051
-14% -$27.9K ﹤0.01% 5115
2024
Q2 		$240K Buy
22,099
+4,272
+24% +$54.7K ﹤0.01% 4615
2024
Q1 		$334K Sell
17,827
-13,647
-43% -$315K ﹤0.01% 4256
2023
Q4 		$683K Sell
31,474
-6,146
-16% -$122K ﹤0.01% 3990
2023
Q3 		$775K Buy
37,620
+21,848
+139% +$631K ﹤0.01% 3659
2023
Q2 		$741K Buy
15,772
+918
+6% +$45.7K ﹤0.01% 3631
2023
Q1 		$623K Sell
14,854
-2,907
-16% -$125K ﹤0.01% 3688
2022
Q4 		$677K Buy
17,761
+6,884
+63% +$263K ﹤0.01% 3833
2022
Q3 		$426K Sell
10,877
-4,620
-30% -$179K ﹤0.01% 4163
2022
Q2 		$500K Sell
15,497
-3,921
-20% -$131K ﹤0.01% 4096
2022
Q1 		$643K Sell
19,418
-8,416
-30% -$316K ﹤0.01% 4062
2021
Q4 		$1.18M Buy
27,834
+5,730
+26% +$240K ﹤0.01% 3635
2021
Q3 		$979K Sell
22,104
-48,342
-69% -$2.22M ﹤0.01% 3717
2021
Q2 		$4M Buy
70,446
+22,135
+46% +$1.56M ﹤0.01% 2474
2021
Q1 		$3.62M Buy
48,311
+4,403
+10% +$361K ﹤0.01% 2491
2020
Q4 		$3.8M Sell
43,908
-35,645
-45% -$2.63M ﹤0.01% 2383
2020
Q3 		$4.86M Buy
79,553
+23,053
+41% +$1.17M ﹤0.01% 2026
2020
Q2 		$2.35M Buy
56,500
+38,732
+218% +$1.41M ﹤0.01% 2488
2020
Q1 		$510K Sell
17,768
-42,063
-70% -$2.44M ﹤0.01% 3597
2019
Q4 		$4.32M Buy
59,831
+34,496
+136% +$4.24M ﹤0.01% 2266
2019
Q3 		$3.55M Buy
25,335
+423
+2% +$70.8K ﹤0.01% 2314
2019
Q2 		$4.56M Sell
24,912
-2,647
-10% -$452K ﹤0.01% 2142
2019
Q1 		$4.38M Buy
27,559
+9,522
+53% +$1.38M ﹤0.01% 2106
2018
Q4 		$1.73M Sell
18,037
-1,629
-8% -$186K ﹤0.01% 2757
2018
Q3 		$2.78M Buy
19,666
+5,459
+38% +$843K ﹤0.01% 2592
2018
Q2 		$2.22M Buy
14,207
+11,578
+440% +$1.82M ﹤0.01% 2645
2018
Q1 		$423K Sell
2,629
-27,905
-91% -$4.74M ﹤0.01% 3809
2017
Q4 		$5.03M Sell
30,534
-9,078
-23% -$880K ﹤0.01% 2053
2017
Q3 		$2.47M Buy
39,612
+39,366
+16,002% +$3.09M ﹤0.01% 2498
2017
Q2 		$20K Sell
246
-748
-75% -$54.1K ﹤0.01% 5546
2017
Q1 		$71K Sell
994
-953
-49% -$55.8K ﹤0.01% 4958
2016
Q4 		$99K Buy
+1,947
New +$91.8K ﹤0.01% 4874
2016
Q2 		– Sell
-350
Closed -$11K – 6503
2016
Q1 		$11K Sell
350
-8,861
-96% -$312K ﹤0.01% 5702
2015
Q4 		$536K Buy
9,211
+8,392
+1,025% +$416K ﹤0.01% 3710
2015
Q3 		$34K Buy
+819
New +$50.5K ﹤0.01% 5332
2015
Q2 		– Sell
-5,264
Closed -$264K – 6691
2015
Q1 		$264K Buy
5,264
+2,431
+86% +$105K ﹤0.01% 4026
2014
Q4 		$104K Buy
+2,833
New +$106K ﹤0.01% 4715

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Royal Bank of Canada's SAGE Position: Q3 2025 in Review

Royal Bank of Canada sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 5,879 shares — an estimated $53K sold.

Royal Bank of Canada first reported a position in SAGE in Q4 2014 and held it in 40 quarters. The position peaked at $5.03M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Royal Bank of Canada reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 5,879 Sage Therapeutics shares in Q3 2025, an estimated $53K.
  • Royal Bank of Canada first reported a position in Sage Therapeutics in Q4 2014 and held it in 40 quarters.
  • Royal Bank of Canada's Sage Therapeutics position peaked at $5.03M in Q4 2017.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.